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Objective: Bladder cancer (BC) is one of the most common noncutaneous malignant cancers with high
mortality and recurrence rates in the general population, particularly in men. We previously reported
detecting dysregulated micro-RNAs (miRNAs) in human BC tissues. Using an miRNA targeting database,
we found that miR-204, which is downregulated in BC, targets the B-cell lymphoma 2 gene (BCL2). We
hypothesized that the overexpression of miR-204 induces apoptosis by repressing BCL2 expression and
causing cancer cell death.
Materials and methods: To overexpress miR-204 in cancer cells, a vector that expresses miR-204 was
transfected into human BC, embryonic kidney, and cervical cancer cells. The expression of miR-204 in the
transfected and mock cells was monitored through miRNA quantitative polymerase chain reactions (Q-
PCRs). Luciferase reporter assays were performed to verify the direct binding of miR-204 to targeted sites
on the BCL2 transcripts. The BCL2 mRNA and protein expression levels in the miR-204-transfected cells
were measured using Q-PCRs and Western blotting, respectively. The cell viability of the miR-204
transfected cells was detected through WST-1 assays. The induction of apoptosis was determined by
the increased release of cytochrome c, cleavage caspase 3, caspase 3/7 activity, and DNA fragmentation.
Results: The expression of miR-204 in the transfected cells was elevated to 6.2-fold, compared with the
controls, and the function of matured miR-204 was conﬁrmed through the luciferase reporter assays. The
expressions of BCL2 mRNA and protein were reduced in the miR-204-transfected cells, which generated
increased DNA fragmentation, caspase 3 cleavage, caspase 3/7 activity, and reduced cell viability.
Cotransfection of the reporter vector that harbored the BCL2 30-untranslated region to compete with
endogenous transcripts partially rescued the apoptosis that was induced by the overexpressed miR-204.
This ﬁnding further supported that miR-204 targeting BCL2 induces apoptosis in BC cells.
Conclusion: miR-204 targets BCL2 in human BC cells. The overexpression of miR-204 in tumors could
thus be a novel strategy for inducing cell death by targeting antiapoptotic BCL2.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In developed countries, bladder cancer (BC) is the ﬁfth most
diagnosed tumor and the second leading cause of death in patients
with genitourinary tract malignancies. In the United States, more
than 73,000 new cases and 14,000 deaths occur annually.1 In 2011,tment of Surgery, Shin Kong
., Shilin Dist., 11101, Taipei,
389404.
.
ociation. Published by Elsevier TaBC was the ninth leading cause of cancer-related deaths in men in
Taiwan.2 BC remains one of the most costly cancers with regard to
treatment and the monitoring of cytological changes through ap-
proaches such as surveillance cystoscopy and periodic imaging.
Despite the existence of appropriate therapies, patients with BC are
continuously at risk of its recurrence and progression to the mus-
cles. Therefore, developing new treatment strategies to reduce
these risks by utilizing novel molecular networks is highly
desirable.
Recent studies have shown that micro-RNAs (miRNAs), which
are key post-transcriptional regulators, act as tumor suppressors oriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
T.I.-S. Hwang et al. / Urological Science 27 (2016) 101e108102oncogenes in cancer progression. Furthermore, since the discovery
of miRNAs, a growing number of studies have reported that dys-
regulated miRNAs are common in human cancer and are involved
in various physiological and pathological processes. A previous
study compared patients' BC tissue with their adjacent normal
bladder tissue and found dysregulated miRNAs, including 19
upregulated and 11 downregulated miRNAs, in the BC tissue.3
These downregulated miRNAs may act as tumor suppressors;
therefore, their decreased expression promotes cancer cell survival.
In silico approaches revealed that miR-204, which is downregulated
in BC, potentially targets the B-cell lymphoma 2 gene (BCL2), a
comprehensively studied antiapoptotic protein. In this paper, we
showed that BCL2 expression is regulated by miR-204, which
directly interacts with the 30-untranslated region (30-UTR) target-
ing site.2. Materials and methods
2.1. Construction of the vectors
To construct the miR-204 expression vector, a paired oligonu-
cleotide consisting of matured miR-204 sequences was synthesized
and cloned into a small-RNA expression vector, pSM, as described in
a previous study.4 This vector generated pSM-204, which expresses
matured miR-204. We also constructed two other miRNA expres-
sion vectors that express miR-15a and miR-214 as the positive and
negative controls,5 and designated them as pSM-15a and pSM-214,
respectively. The oligonucleotides are listed in Table 1.
To test whether pSM-204 or pSM-15a generates matured and
functional miRNAs, we constructed reporter vectors (pmirGLO;
Promega, Madison, WI, USA) with antisense [i.e., positive targetingTable 1
List of the oligonucleotides and polymerase chain reaction primer pairs used
Name Sequences (50/30)
Oligonucleotides for the construction of miRNA expression vectors
Has-miR-204 (Top) TGCTGTTCCCTTTGTC
Has-miR-204 (Bot) CCTGTTCCCTTTGTCA
Has-miR-15 (Top) TGCTGTAGCAGCACA
Has-miR-15 (Bot) CCTGTAGCAGCACATA
miRNA primer for miRNA Q-PCR
miR-204 TTCCCTTTGTCATCCTA
Oligonucleotides for the construction of the reporter vectors (the miRNA-ta
pmiR-204PTS (Top) CTAGCAGGCATAGGA
pmiR-204PTS (Bot) TCGAGTTCCCTTTGTC
pmiR-204MTS (Top) CTAGCTTCCCTTTGTC
pmiR-204MTS (Bot) TCGAGAGGCATAGGA
pmiR-Bcl2-204TS (Top) TCGAGGCAAAACGTC
pmiR-Bcl2-204TS (Bot) GGCCGCATAAATGAT
pmiR-Bcl2-204MTS (Top) TCGAGGCAAAACGTC
pmiR-Bcl2-204MTS (Bot) GGCCGCATAAATGAT
pmiR-15PTS (Top) CTAGCCACAAACCATT
pmiR-15PTS (Bot) TCGAGTAGCAGCACA
pmiR-15MTS (Top) CTAGCTAGCAGCACA
pmiR-15MTS (Bot) TCGAGCACAAACCAT
pmiR-Bcl2-15TS (Top) TCGAGAAGTGATGAA
pmiR-Bcl2-15TS (Bot) GGCCGCTTTTGGCAG
pmiR-Bcl2-15MTS (Top) TCGAGAAGTGATGAA
pmiR-Bcl2-15MTS (Bot) GGCCGCTTTTGGCAG
The Q-PCR primers
HsBcl2-5QP1 CTGTGGTCCACCTGAC
HsBcl2-3QP1 CGTACAGTTCCACAAA
HsBcl2l2-5QP1 GAGCCATATAGTTCCT
HsBcl2l2-3QP1 TAGAATAAGTGGGGA
EGFP-5QP1 CGACGGCAACTACAA
EGFP-3QP1 TAGTTGTACTCCAGCT
Bot ¼ bottom; EGFP ¼ enhanced green ﬂuorescent protein; miRNA ¼ microsite, (PTS)] sequences or sense [i.e., mutated targeting site (MTS)]
sequences of miR-204 and miR-15a, respectively. This cloning step
generated pmiR-204PTS, pmiR-204MTS, pmiR-15aPTS, and pmiR-
15aMTS. To construct reporter plasmids containing an miR-204
targeting site in the 30-UTR of BLC2 for the luciferase assay, dou-
ble strand oligonucleotides bearing 19 bases upstream and 11 bases
downstream of the miR-204 or miR-15a seed sequences of the BCL2
30-UTRs were cloned into the pmirGLO vector and designated as
pmiR-Bcl2-204TS and pmiR-Bcl2-15TS, respectively. The vectors
containing an MTS (i.e., pmiR-Bcl2-204MTS and pmiR-Bcl2-15MTS)
were constructed through a similar cloning step by using the
reverse seed sequences of miR-204 and miR-15a, and these vectors
served as the negative controls. The oligonucleotides are listed in
Table 1.2.2. Cell culture and transfection
Human cancer cell lines were obtained from the American Type
Culture Collection (Manassas, VA, USA) and maintained at 37C
under 5% carbon dioxide. The human BC cell line T24 (HTB-4) was
cultured in an Roswell Park Memorial Institute (RPMI)-1640 me-
dium (Invitrogen Carlsbad, CA, USA). The human embryonic kidney
T293 (CRL-11268) cell line and cervical cancer HeLa (CCL-2) cell line
were cultured in Dulbecco's modiﬁed Eagle's medium (Invitrogen).
The media were supplemented with 10% fetal bovine serum (Invi-
trogen), 2mMGlutaMAX-I (Invitrogen), and 100 units/mL penicillin
and 100 mg/mL streptomycin (Invitrogen). Cells were transfected
using miRNA-expressing vectors with or without reporter con-
structs by exposure to a polymer-based transfection reagent
(Transfec 293; GeneDireX, Gueishan Township, Taiwan) forin this study.
ATCCTATGCCTGTTTTGGCCACTGACTGACAGGCATAGTGACAAAGGGAA
CTATGCCTGTCAGTCAGTGGCCAAAACAGGCATAGGATGACAAAGGGAAC
TAATGGTTTGTGGTTTTGGCCACTGACTGACCACAAACCTATGTGCTGCTA
GGTTTGTGGTCAGTCAGTGGCCAAAACCACAAACCATTATGTGCTGCTAC
TGCCT
rgeting sites are underlined and the miRNA seed sequences are boxed)
TGACAAAGGGAAGATATCAGGCATAGGATGACAAAGGGAAC
ATCCTATGCCTGATATCTTCCCTTTGTCATCCTATGCCTG
ATCCTATGCCTGATATCTTCCCTTTGTCATCCTATGCCTC
TGACAAAGGGAAGATATCAGGCATAGGATGACAAAGGGAAG
GAATCAGCTATTTACTGCCAAAGGGAAATATCATTTATGC
ATTTCCCTTTGGCAGTAAATAGCTGATTCGACGTTTTGCC
GAATCAGCTATTTACTGCCTTTCCCTTATATCATTTATGC
ATAAGGGAAAGGCAGTAAATAGCTGATTCGACGTTTTGCC
ATGTGCTGCTAGATATCCACAAACCATTATGTGCTGCTAC
TAATGGTTTGTGGATATCTAGCAGCACATAATGGTTTGTGG
TAATGGTTTGTGGATATCTAGCAGCACATAATGGTTTGTGC
TATGTGCTGCTAGATATCCACAAACCATTATGTGCTGCTAG
TATGGAATATCCAATCCTGTGCTGCTATCCTGCCAAAAGC
GATAGCAGCACAGGATTGGATATTCCATATTCATCACTTC
TATGGAATATCCAATCCTGTAGCAGCATCCTGCCAAAAGC
GATGCTGCTACAGGATTGGATATTCCATATTCATCACTTC
CCTCCGC
GGCATCCCAGC
TGGGA
GTGGGA
GAC
TGTGC
-RNA; Q-PCR ¼ quantitative polymerase chain reaction.
Figure 1. Elevation of miR-204 expression in T24, 293T, and HeLa cells transfected
with pSM-204. Cells were harvested 24 hours post-transfection while coexpressed
EGFP was detected under ﬂuorescent microscopy. Total RNA was extracted, reverse
transcripted, and followed by an miRNA Q-PCR. The expression of miR-204 was
normalized using U6 RNA. The data represent three independent experiments and are
expressed as the mean percentage ± the standard deviation, relative to the vector-only
control (i.e., pSM). EGFP ¼ enhanced green ﬂuorescent protein; miRNA ¼ micro-RNA;
Q-PCR ¼ quantitative polymerase chain reaction. *p < 0.05.
T.I.-S. Hwang et al. / Urological Science 27 (2016) 101e108 10324 hours. In some samples, 400 mg/mL G418 was added to the
medium for 24 hours before the cells were harvested.
2.3. Real-time quantitative polymerase chain reaction
The NCode miRNA First-strand cDNA Synthesis Kit (Invitrogen)
and NCode SYBR Green miRNA qRT-PCR Kit (Invitrogen) were used
to detect the expression of miR-204 in the transfected cells, as
described in a previous study.4 To normalize the relative abundance
of miRNAs, U6 RNA was employed as an internal control. The
expression of BCL2, MCL-1, and BAD was measured in the 24-hour
post-transfected cells. The total RNA was isolated using a TRIzol
reagent (Invitrogen). The RNA quality and yield were measured
using a spectrophotometer (Nanodrop 2000; Thermo Scientiﬁc,
Waltham, MA, USA). Reverse transcription and quantitative poly-
merase chain reaction (Q-PCR) were performed, as described pre-
viously.6 Quantiﬁcation was conducted in triplicate, and the data
were derived from three independent experiments. Enhanced
green ﬂuorescent protein (EGFP) coexpressed with miR-204 was
used as an internal standard to eliminate potential differences in
transfection efﬁciency. Data were collected from triplicate results
from different batches of RNA samples. These data are expressed as
the mean ± the standard deviation (SD). The speciﬁc primer pairs
used in this study are listed in Table 1.
2.4. Luciferase reporter assays
The 293Tcells were cotransfectedwith pSM-204, miR-15a, pSM-
15 or a control (i.e., pSM), and reporter plasmids. Fireﬂy and Renilla
luciferase activity were measured consecutively at 24 hours post-
transfection in accordance with the manufacturer's instructions
in the Dual-Luciferase Kit (Promega). The relative protein levels
were expressed as FireﬂyeRenilla luciferase ratios. The data were
retrieved from triplicate wells through three independent experi-
ments, and are expressed as the mean ± SD.
2.5. Detection of BCL2 protein levels through Western blotting
At 24 hours post-transfection, the medium was replaced with a
complete medium containing G418 (400 mg/mL). Protein samples
were collected at 96 hours post-transfection using a radio-
immunoprecipitation assay (RIPA) buffer (150mM sodium chloride,
10mM Tris, pH 7.2, 0.1% sodium dodecyl sulfate (SDS), 1.0% Triton X-
100, 5mM EDTA, pH 8.0) containing a 1 protease inhibitor cocktail
(Roche, Basel, Switzerland). The protein concentration was deter-
mined using a Micro BCA Protein Assay Kit (Pierce Waltham, MA,
USA).Westernblottingwassubsequentlyperformed, asdescribed ina
previous study.7 Band signalswere acquired in the linear range of the
scannerusingdensitometry software (TotalLabQuantV1.0.8, TotalLab
Ltd., Newcastle upon Tyne, UK). The ratio between the BCL2 and the
EGFP bands was used to quantitate BCL2modulation by miR-204.
2.6. Cell viability and detection of apoptosis
For cell viability assays, the cells were transfectedwith pSM-204
with or without reporter vectors, as described in section 2.2. Cell
viability was measured at 24 hours post-transfection using aWST-1
reagent (Roche). We detected the release of cytochrome c from the
mitochondria to the cytosol and the presence of caspase 3/7 activity
in the transfected cells for apoptosis assessment. The cytosol pro-
tein fractions in the transfected cells were isolated using the
Mitochondria Isolation Kit for Cultured Cells (Thermo Scientiﬁc) in
accordance with the manufacturer's instructions, electrophoresed
on 15% polyacrylamide gel, and then analyzed through Western
blotting using an anticytochrome c antibody (#136F3; CellSignaling Technology, Beverly, MA, USA), voltage-dependent anion
channel [(VDAC), #D73D12; Cell Signaling Technology], and
enhanced chemiluminescence, as described previously. The cas-
pase 3/7 activity was assayed, as indicated in a previous study.8 The
measured ﬂuorescence was normalized to the ﬂuorescence of the
nontransfected cell lysates, and the caspase 3/7 activities were
normalized to the cell viability.
2.7. Statistical analysis
Data are presented as the mean ± SD of the results of three
independent experiments, each of which was performed in tripli-
cate. The Student t test was employed to identify signiﬁcant dif-
ferences between the experimental groups. A value of p < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Elevated level of miR-204 in pSM-204 transfected cells
To study the effect of miR-204 on the expression of putative
targets in cancer cells, we elevated the expression of miR-204 in BC
(i.e., T24) cells. Embryonic kidney (i.e., 293T) cells and cervical
cancer (i.e., HeLa) cells were the reference cancer cells. As antici-
pated, miR-204 expressionwas higher in pSM-204-transfected cells
than in the controls. As displayed in Figure 1, miR-204 transcripts
were elevated 3.92 ± 0.42, 6.21 ± 0.24, and 5.67 ± 0.31 times in the
T24, 293T, and HeLa cells, respectively.
3.2. miR-204 interacts directly with the predicted targeting site on
the 30-UTR of BCL2
To identify putative miR-204 targets that may contribute to
tumorogenesis, we employed an in silico strategy using miRNA
target databases such as PicTar9 and TargetScan.10 The well-known
antiapoptotic BCL2 gene was identiﬁed as a putative miR-204 tar-
geted gene. The prediction results and TargetScan score are listed in
Figure 2A. The BCL2-like 2 (BCL2L2) gene is an miR-204 targeted
gene.11 We thus included the predictedmiR-204/BCL2L2 results as a
Figure 2. Effect of the putative miR-204 targeting site derived from the BCL2 30-UTR on luciferase expression. (A) The putative binding sites of miR-204 in the BCL2 and BCL2L2 30-
UTR regions, as detected using the TargetScan database. (B) The BCL2 30-UTR sequences that contain the putative miR-204 targeting site are highly conserved among vertebrate
species. The ﬁgure is derived from the TargetScan results, and the miR-204 seed sequences are indicated with a white background. (C) The predicted RNA duplex structure of miR-
204/BCL2 and miR-204/BCL2L2 binding generated through the RNA hybrid. Luciferase activity in the 293T cells that are transiently cotransfected with the miR expression vector for
the sense strand of miR-204 and (D) the positive and negative control reporter vectors (PTS and MTS, respectively) or (E) 30-UTR of the BCL2 reporter vectors (TS and MTS). miR-15a
that had been demonstrated to target BCL2 is the positive control. The data represent the mean± the standard deviation of three independent experiments, each of which was
performed in triplicate. mfe ¼ minimum free energy; MTS ¼ mutated targeting site; PTS ¼ positive targeting site; TS ¼ targeting site; UTR ¼ untranslated region. *p < 0.05.
T.I.-S. Hwang et al. / Urological Science 27 (2016) 101e108 105reference. Information on conserved binding sites on the 30-UTR of
BCL2 among vertebrate species such as humans, chimpanzees,
dogs, cats, rats, and mice were retrieved from the TargetScan pro-
gram (Figure 2B). This ﬁnding suggested that miR-204 targeting
BCL2 is preserved during evolution. The free energy of miR-204
binding to the BCL2 and BCL2L2 binding sites was calculated, us-
ing the RNA hybrid, as 19.4 kcal/mol and 18.3 kcal/mol,
respectively. These results further emphasized that the targeting
sequence within the BCL2 30-UTR is highly likely to be miR-204
binding. The predicted structures of miR-204 binding to BCL2 and
BCL2L2 are displayed in Figure 2C. To substantiate that miR-204
directly regulates BCL2, we ﬁrst tested whether the pSM-derived
vectors generated functional matured miRNAs. As shown in
Figures 2D and 2E, luciferase activity was reduced signiﬁcantly in
the cells that were cotransfected with pSM-204 and pmiR-204PTS
and cells cotransfected with pSM-15 and pmiR-15PTS. None of
the miRNA expression plasmids had a regulatory effect on the
pmiR-GLO reporter vector with the MTSs (Figure 2D). When
replaced, the reporter vectors to pmiR-Bcl2-204TS and pmiR-Bcl2-
15TS bore the BCL2 targeting sequence of miR-204 and miR-15a,
respectively, the luciferase activities were decreased (Figure 2E).
We cloned reporter vectors (pmiR-Bcl2-204MTS and pmiR-Bcl2-
15MTS) containing the reversed seed sequences of miR-204 and
miR-15a on the 30-UTR of BCL2 as the MTSs. As anticipated, these
mutants eliminated the interaction between miR-204 and miR-15a
with the 30-UTR of BCL2 (Figure 2E). These results indicated that
pSM-204 and pSM-15 generated functional and matured miRNAs
that directly interacted with the 30-UTR of BCL2.
3.3. Decreased levels of BCL2 mRNA and protein in pSM-204
transfected T24 cells
We tested the level at which BCL2 was downregulated by the
elevated miR-204 because miRNAs may suppress the expression of
a speciﬁc target by reducing mRNA stability or blocking translation.
The expression of BCL2mRNA in the pSM-204 transfected cells was
measured through Q-PCR at 48 hours post-transfection. The BCL2
mRNA expression levels were reduced to 52.01% ± 8.81%,
35.12% ± 6.18%, and 51.03% ± 2.21% in the T24 cells, 293T cells, and
HeLa cells, respectively, comparedwith the vector-only control (i.e.,
pSM; Figure 3A, left histogram). As a positive control, the mRNA
expression of BCL2L2 was reduced to 64.31% ± 4.81%,
50.13% ± 3.71%, and 55.81% ± 6.21% in the T24 cells, 293T cells, and
HeLa cells, respectively (Figure 3A, right histogram).
We next examined the BCL2 protein level in response to the
elevated miR-204 expression. As displayed in Figure 3B, the BCL2
level was reduced in the pSM-204 transfected cells, compared with
the vector-only control (T24 cells, 54.67% ± 18.23%; 293T cells,
28.35% ± 9.52%). These data suggested that miR-204 suppressed
BCL2 expression in RNA and in the protein.
3.4. Suppression of BCL2 by miR-204 induced apoptosis and
reduced cell viability in T24 cells
BCL2 is an antiapoptotic protein that inhibits apoptosis by inter-
acting with proapoptotic members of the BCL2 family such as BAD,
BAX, andBID. DecreasedBCL2 expressiondisrupts the balanceof anti-
and proapoptotic homodimers, and thus activates an apoptotic
cascade by disrupting the mitochondria.12 We thus investigated the
induced apoptosis in pSM-204-transfected cells by detecting the
cytochrome c release, cleavage of caspase 3, and activation of caspase
3/7 activities. As illustrated in Figure 4A, cytochrome c was released
from the mitochondria to the cytosol in pSM-204-transfected
T24 cells, which indicated that miR-204 targeting of BCL2 causes an
imbalance in anti- and proapoptotic protein levels and creates amitochondria-dependent apoptotic pathway. Furthermore, the
expression of BAD and BAX was unaffected, whereas the expression
of cleaved-caspase 3 was increased in the pSM-204-transfected cells
(Figure 4B). Furthermore, caspase 3/7 activationwas also detected in
cells that were transfected with pSM-204, which indicated that it
could be suppressed by cotransfection with reporter constructs
(Figure 4C). These results conﬁrm that BCL2 downregulation bymiR-
204 triggers mitochondria-dependent apoptosis, and that miR-204
expression is crucial for thismechanism. To investigate the biological
importance of BCL2 as a target of miR-204, we measured the cell
viability in the pSM-204 transfected cells. As shown in Figure 4D, cell
viability was reduced in cells that were transfected with pSM-204
(T24 cells, 62.10% ± 5.18%; 293T cells, 53.12% ± 2.34%), compared
with the vector control.
To further conﬁrm that miR-204 reduces cell viability by tar-
geting BCL2, a rescue experiment was performed by cotransfecting
the reporter constructs harboring the miR-204-positive targeting
sequences (i.e., pmiR-204PTS) or the 30-UTR of BCL2 (i.e., pmiR-
Bcl2-204TS). These reporters generated miR-204-targeting se-
quences to compete with exogenous miR-204 or endogenous BCL2
transcripts. As displayed in Figure 4D, cotransfecting pSM-204 with
pmiR-204PTS restored cell viability in the T24 and 293T cells,
whereas cotransfecting pSM-204 with pmiR-Bcl2-204TS partially
rescued cell viability. These results indicated that miR-204 targets
BCL2 and reduces cell viability; however, other mRNA targets of
miR-204 may also have contributed to the loss in viability because
cell viability was not fully recovered in the cells that were
cotransfected with pmiR-Bcl2-204TS and pSM-204.
4. Discussion
The imbalance of anti- and proapoptotic protein is a critical
mechanism of cancer progression. Upregulation of BCL2 has been
demonstrated in numerous cancer types,13 and high BCL2 expres-
sion has been detected in androgen-independent prostate cancer.14
Therefore, BCL2 is a potentially viable therapeutic target in cancer
treatment.15 Downregulation of miR-204 has been reported in
human breast cancer,16 BC,17 renal clear cell carcinoma,18 head and
neck tumors,19 leukemia,20 and endometrioid adenocarcinoma.21 In
the present study, we showed that forced expression of miR-204 in
cancer cells such as T24 and 293T cells, induced apoptosis by
directly targeting BCL2. These results indicated that the interaction
between miR-204 and BCL2 may be universal. For the positive
control, we also demonstrate that another antiapoptotic protein,
BCL2L2, was targeted by miR-204.
The elevation of miR-204 expression signiﬁcantly reduced the
cell viability of T24 and 293T cells. Furthermore, the viability of
these cells was fully restored and partially restored by cotrans-
fecting reporter constructs bearing miR-204 PTS (pmiR-204PTS)
and a BCL2 targeting site (pmiR-Bcl2-204TS), respectively. These
results indicated that BCL2 is not the only target of miR-204 that
reduces cell viability. BCL2L2 is reportedly an antiapoptotic target of
miR-204 in human trabecular meshwork (HTM) cells. The elevation
of miR-204 in HTM cell lines also induced apoptosis and caused cell
death.11 This further supported the notion that miR-204 functions
as a tumor-suppressing miRNA by targeting antiapoptotic genes.
In conclusion, our results revealed that BCL2 is a direct target of
miR-204. Consistent with the decrease in BCL2 expression, miR-204
overexpression resulted in signiﬁcant alteration in cancer cells such
as increased apoptosis and cell death. Our results speciﬁcally
conﬁrmed the direct targeting of miR-204 to the 30-UTR of BCL2 and
demonstrated a signiﬁcant decrease in BCL2 expression by miR-
204. These data collectively suggested that decreased miR-204
expression in cancers may increase BCL2 expression and promote
cancer progression. The induction of apoptosis by miR-204 in these
Figure 3. The expression of BCL2 is repressed by miR-204. (A) The relative mRNA levels of BCL2were measured in cells that were transfected with pSM-204 and compared with the
vector-only controls (i.e., pSM) through Q-PCR at 48 hours post-transfection. As a validated miR-204 target, the mRNA level of BCL2L2 was measured as the positive control. (B)
Western blotting results for the BCL2 protein level in pSM-204 transfected cells. Cells were collected at 72 hours post-transfection. The b-actin and coexpressed EGFP were detected
as the loading control. The relative protein levels for each treatment during three independent experiments were quantiﬁed, as displayed in the right panel. EGFP ¼ enhanced green
ﬂuorescent protein; miRNA ¼ micro-RNA; Q-PCR ¼ quantitative polymerase chain reaction. *p < 0.05.
T.I.-S. Hwang et al. / Urological Science 27 (2016) 101e108106cancer cells provided further evidence that miR-204 suppresses
cancer growth, even in miR-204-positive cancer cells (i.e., 293T
cells). Hence, future clinical studies that aim to elucidate the rela-
tionship between miR-204 and antiapoptotic genes may providefurther insight into the design of novel molecular therapies for BC,
and, more importantly, in the inhibition of cancer progression and
subsequent low overall survival. The ﬁndings of this study offer
insight into an innovative approach that utilizes the miRNA
Figure 4. Repression of BCL2 by miR-204 induces apoptosis and reduces cell viability. Cells are transfected with the indicated vectors. At 72 hours post-transfection, the following
were detected: (A) cytochrome C release, (B) the expression of BAD, BAX, and cleaved-caspase 3, (C) caspase-3/7 activity, and (D) cell viability. Reporter vectors that expressed an
miR-204-positive targeting sequence (i.e., pmiR-204PTS) or contained BCL2 30-UTR (i.e., pmiR-Bcl2-204TS) are cotransfected in the rescue experiments. Cyto. C ¼ cytochrome c;
EGFP ¼ enhanced green ﬂuorescent protein; UTR ¼ untranslated region. *p < 0.05.
T.I.-S. Hwang et al. / Urological Science 27 (2016) 101e108 107pathway (i.e., the bladder maximizes the effect of gene therapy by
using miRNAs because of its accessibility and closed environment).Conﬂicts of interest
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